NCT02336516View on ClinicalTrials.gov

Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Haemolytic and Uremic Syndrome
Interventions
DRUG

Azithromycin

ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days

DRUG

Placebo (glucose solution 10%)

Trial Locations (1)

34295 Montpellier cedex 5

Arnaud de Villeneuve Hospital, Montpellier

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02336516 - Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome | Biotech Hunter | Biotech Hunter